M N Sabbagh

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study

George Jewell, Eric M Reiman, Ranjan Duara, 2014, Molecular Psychiatry.

Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD.

B. Reisberg, M. Sabbagh, T. Beach, 2010, Current Alzheimer research.

Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease.

C. Adler, D. Connor, M. Sabbagh, 2007, Parkinsonism & related disorders.

HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier.

D. Sparks, D. Connor, M. Sabbagh, 2002, The journal of nutrition, health & aging.

Quantitative EEG as a predictive biomarker for Parkinson disease dementia

C. Adler, M. Sabbagh, J. Caviness, 2011, Neurology.

Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol‐Lowering Treatment (ADCLT) trial

D L Sparks, D. Sparks, D. Connor, 2006, Acta neurologica Scandinavica. Supplementum.

Correlations between SPECT regional cerebral blood flow and psychometric testing in patients with Alzheimer's disease.

M. Sabbagh, R. Doody, P. Massman, 1997, The Journal of neuropsychiatry and clinical neurosciences.